

Free CME Web cast

Designed for physicians, pharmacists, nurses, psychologists, case managers, physician assistants, social workers and counselors

Functional Outcomes for Our Mentally Ill Patients

Presenters:

Stephen R. Marder, MD
Professor, Semel Institute for Neuroscience and Human Behavior at UCLA
Director, MIRECC, Greater Los Angeles Veterans Affairs Medical Center

Michael F. Green, PhD
Professor, Semel Institute for Neuroscience and Human Behavior at UCLA
Director of the Treatment Unit, VA VISN 22 Mental Illness Research, Education and Clinical Center

Moderator:

Peter F. Buckley, MD
Professor and Chairman
Department of Psychiatry and Health Behavior
Medical College of Georgia

Functional Outcomes for Our Mentally Ill Patients

Presenters:

Stephen R. Marder, MD
Professor, Semel Institute for Neuroscience and Human Behavior, UCLA
Director, MIRECC, Greater Los Angeles Veterans Affairs Medical Center

Michael F. Green, PhD
Professor, Department of Psychiatry and Biobehavioral Sciences, UCLA
Director of the Treatment Unit, VA VISN 22 Mental Illness Research, Education and Clinical Center

Moderator:

Peter F. Buckley, MD
Professor and Chairman
Department of Psychiatry and Health Behavior
Medical College of Georgia



To register, visit

www.i3dln.com

or call

1-800-326-9166

Learning Objectives:

At the end of this educational activity, participants should be able to:

1. Review the impact of symptomatology, cognition, side effects and treatment adherence on functional outcomes in people with mental illness
2. Discuss the concept of recovery and remission as a treatment goal in mentally ill patients
3. Discuss strategies to optimize functional outcomes by treating behavioral symptoms, minimizing side effects, providing psychosocial support and improving cognition

Statement of Need:

Treatment outcomes for people with severe mental illness have traditionally been poor. In the past, the primary treatment goal was to decrease symptoms. Newer approaches to treatment aim not only to reduce symptomatology and decrease relapses, but also to improve vocational and social outcomes. This broader view of treatment embraces overall mental and physical well-being rather than simply the absence of

illness. Recovery and remission have become an increasingly prominent paradigm for the treatment of mental illness. In working toward these goals, a range of interventions must be incorporated into long-term treatment strategies, including not only pharmacologic interventions, but also psychosocial therapies as well. Newer treatment planning increasingly focuses on functional outcomes by providing treatment and recovery-oriented services to people with schizophrenia. Likewise, focusing on patient satisfaction, improving tolerability by limiting side effects (e.g., weight gain, sexual dysfunction, sedation) and maximizing cognitive functioning are all important aspects of treating in the framework of recovery and improving functional outcomes. This educational program will review the impact of symptomatology, cognition, side effects and treatment adherence on functional outcomes in people with mental illness, discuss the concept of recovery and remission as a treatment goal in mentally ill patients, and discuss strategies to optimize functional outcomes by treating behavioral symptoms, minimizing side effects, providing psychosocial support and improving cognition.

Accreditation Statements/Credit Designation:


CME LLC is accredited by the ACCME to provide continuing medical education for physicians.

CME LLC designates this educational activity for a maximum of 1.0 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.

CME credits from activities presented by ACCME accredited providers may be used toward American Osteopathic Association (AOA) Category 2-A requirements.

CME LLC is registered with CE Broker as an approved provider of continuing medical education for Florida-licensed physicians, osteopathic physicians, physician assistants and nurses.

Participants will receive credits through an on-line process or by submitting paperwork to the on-site coordinator.



CME LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program provides 0.1 CEU (UPN 817-000-06-058-H01).

CME LLC is approved by the California Board of Registered Nursing, Provider No. CEP12748, and designates this educational activity for 1.0 contact hour for nurses.

The American Nurses Credentialing Center (ANCC) accepts AMA PRA category 1 credit toward recertification requirements.

CME LLC is approved by the American Psychological Association to sponsor continuing education for psychologists. CME LLC maintains responsibility for the program.

Course meets the qualifications for the 1.0 hour of continuing education credit for MFTs and/or LCSWs as required by the California Board of Behavioral Sciences (Provider PCE #239).

CME LLC is approved by the Illinois Department of Regulation (License #159-00268) and the Texas State Board of Social Worker Examiners (Sponsor #CS3798) to provide continuing education for Social Workers. This program is approved for 1.0 hour of continuing education credit for Social Workers.

Application has been made with the Commission for Case Manager Certification for 1.0 clock hour.

Release Date: 3/2006
Expiration Date: 2/2007

Commercial Support:

This activity is supported in part by an *unrestricted* educational grant to CME LLC, in partnership with i3 DLN, from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.



To register, visit www.i3dln.com. For more information, call **1-800-326-9166**

This email message is an advertisement.

If you wish to no longer receive our announcements, simply [request to be removed](#) from this list.

This email is created in pursuit of CME/CE content and was created with the ACCME guidelines in mind. The information contained in this electronic e-mail transmission and any attachments are intended only for the use of the individual or entity to whom or to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, or the employee or agent responsible for delivering this communication to the intended recipient, you are hereby notified that any dissemination, distribution, copying or disclosure of this communication and any attachment is strictly prohibited. If you have received this transmission in error, please notify the sender immediately by telephone and electronic mail, and delete the original communication and any attachment from any computer, server or other electronic recording or storage device or medium. Receipt by anyone other than the intended recipient is not a waiver of any attorney-client, physician-patient or other privilege. Thank you.

i3 DLN
111 West Main Street
Boalsburg, PA 16827
info@i3dln.com